Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
Portfolio Pulse from
Phio Pharmaceuticals has completed enrollment for the second cohort in its Phase 1b clinical trial for PH-762, with promising results showing significant tumor clearance in patients. The trial has expanded to six sites across the U.S.
November 19, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phio Pharmaceuticals has completed enrollment for the second cohort in its Phase 1b trial for PH-762, showing promising results with significant tumor clearance in patients. The trial has expanded to six sites across the U.S.
The completion of enrollment and promising results in the Phase 1b trial for PH-762 are positive indicators for Phio Pharmaceuticals. The expansion to six sites suggests strong progress and potential for future success, likely boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100